Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
Author(s) -
Matteo Simonelli,
Elena Garralda,
Ferry A.L.M. Eskens,
Marta Gil-Martín,
ChungJen Yen,
Radka Obermannová,
Yee Chao,
Sara Lonardi,
Bohuslav Melichar,
V. Moreno,
MingLung Yu,
Alberto Bongiovanni,
Emiliano Calvo,
Sylvie Rottey,
J-P. Machiels,
Antonio González-Martı́n,
Luis PazAres,
Christie Chang,
W. P. Mason,
ChiaHui Lin,
David A. Reardon,
María Vieito,
Armando Santoro,
Robin Meng,
Giovanni Abbadessa,
Fatima Menas,
H. Lee,
Q. Liu,
Cécile Combeau,
Nils Ternès,
Samira ZitiLjajic,
Christophe Massard
Publication year - 2022
Publication title -
esmo open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.409
H-Index - 31
ISSN - 2059-7029
DOI - 10.1016/j.esmoop.2022.100562
Subject(s) - medicine , atezolizumab , oncology , adverse effect , tolerability , cancer , immunotherapy , pembrolizumab
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom